Angiotensin 1-7 promotes cardiac angiogenesis following infarction.

Abstract:

:Angiogenesis is central to cardiac repair following myocardial infarction (MI). Cardiac angiotensin converting enzyme (ACE)2 significantly increased postMI, which is coincident with activated angiogenesis. The function of ACE2 is to generate angiotensin (Ang)1-7, an active peptide with cellular actions mediated by Mas receptors. The current study is to determine whether Ang(1-7) is involved in cardiac angiogenesis and facilitates cardiac repair. In the first portion of the study, the temporal expressions of cardiac ACE2 and Mas receptors were detected in rats with MI. In the second portion, MI rats were treated with or without a Mas receptor antagonist, A779 (1mg/kg/day given by minipump) for 7 days. Vascular density and expression of angiogenic mediators in the infarcted myocardium and cardiac function were examined. Compared to controls, ACE2 and Mas receptor levels were significantly increased in the infarcted myocardium for 4 weeks of the observation period. Newly formed vessels were evident in the infarcted myocardium at day 7. Mas receptor blockade significantly reduced vascular density in the infarcted myocardium and impaired ventricular function. In addition, A779 treatment significantly suppressed the cardiac expressions of vascular endothelial growth factor (VEGF)-D and matrix metalloproteinase (MMP)-9 but not expression of other angiogenic mediators, including monocyte Chemoattractant protein (MCP-1), VEGF-C, transforming growth factor (TGF)-β1 and integrin β3. These observations indicate that Ang(1-7) promotes angiogenesis via stimulating the expression of cardiac VEGF-D and MMP-9, thus facilitating cardiac repair and ventricular function.

journal_name

Curr Vasc Pharmacol

authors

Zhao W,Zhao T,Chen Y,Sun Y

doi

10.2174/15701611113119990006

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

37-42

issue

1

eissn

1570-1611

issn

1875-6212

pii

CVP-EPUB-20130429-6

journal_volume

13

pub_type

杂志文章
  • Pleiotropic effects of ARB in vascular metabolism--focusing on atherosclerosis-based cardiovascular disease.

    abstract::The renin-angiotensin system (RAS) plays an essential role in fluid and electrolyte homeostasis and the regulation of vascular tone; however, dysregulation and over-activation of the RAS lead to the pathogenesis of various cardiovascular diseases. The RAS is closely associated with NADPH oxidase, a major enzymatic sou...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111794519273

    authors: Honjo T,Yamaoka-Tojo M,Inoue N

    更新日期:2011-03-01 00:00:00

  • Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial.

    abstract:OBJECTIVE:To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment. METHODS:Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2174/1570161112666141014151858

    authors: Wang LY,Tang JY,Liu J,Lu W,Yu YN,Chen BW,Wu HL,Su LY,Jing ZW,Hu SY,Liu XL,Yang XY,Li GX,Dong B,Wang DH,Xue J,Wang XF,Li ZM,Liu SR,Liu SS,Chen QG,Zhang L,Wang Z,Shen CT,Wang YY

    更新日期:2015-01-01 00:00:00

  • Effects of kallistatin on oxidative stress and inflammation on renal ischemia-reperfusion injury in mice.

    abstract:BACKGROUND:Kallistatin (KS) is a serine proteinase. The result of KS on 'Renal Ischemia- Reperfusion Injury' (IRI) has not clearly been researched. In this study, investigative research has been conducted to draw results on the administration of human KS on kidney response conducted within a mouse model of IRI. MATERI...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161113666150204142716

    authors: Zhou S,Sun Y,Zhuang Y,Zhao W,Chen Y,Jiang B,Guo C,Zhang Z,Peng H,Chen Y

    更新日期:2015-01-01 00:00:00

  • Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction.

    abstract::Bladder outlet obstruction (BOO) is a common disorder that is associated with urinary tract symptoms. Nitric oxide (NO), synthesized by NO synthase (NOS) is a potent vasodilator that is present throughout the urinary tract and the corpus cavernosum. Endothelin-1 (ET-1) conversely is a potent vasoconstrictor peptide th...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161033386600

    authors: Khan MA,Thompson CS,Dashwood MR,Mumtaz FH,Morgan RJ,Mikhailidis DP

    更新日期:2003-03-01 00:00:00

  • Calcifediol - more than the stepchild of CKD-MBD therapy?

    abstract::In patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), 25OH-vitamin D (calcidiol) deficiency or insufficiency is a common finding with high prevalence. Numerous epidemiological studies have found an independent association of low levels of calcidiol with increased morbidity and mortality. Wi...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/15701611113119990027

    authors: Brandenburg VM,Kruger T

    更新日期:2014-03-01 00:00:00

  • Role of pharmacotherapy in cardiac ion channelopathies.

    abstract::In the last decade there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VA) and Sudden Cardiac Death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10-15% of SCD occurs in the presence of structurally ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016109788340794

    authors: El-Sherif N,Pedalino R,Himel H 4th

    更新日期:2009-07-01 00:00:00

  • Editorial: aliskiren/amlodipine single-pill combinations: more evidence in favour of combination formulations for the treatment of hypertension.

    abstract::In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively. ...

    journal_title:Current vascular pharmacology

    pub_type: 评论,社论

    doi:10.2174/157016112803520783

    authors: Katsiki N,Athyros VG,Mikhailidis DP,Karagiannis A

    更新日期:2012-11-01 00:00:00

  • Oxidative-nitrosative stress in hypertension.

    abstract::Reactive oxygen species (ROS) are important signaling molecules in the vasculature. However, when there is imbalance between their occurrence and antioxidant defense mechanisms, ROS can contribute to the vascular abnormalities that lead to hypertension. Evidence accumulated in the last decade strongly supports the not...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161054368643

    authors: Escobales N,Crespo MJ

    更新日期:2005-07-01 00:00:00

  • Prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?

    abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH), are major health problems worldwide. Genetics may play a role in the pathogenesis of NAFLD/NASH. AIM:To investigate the prevalence of NAFLD/NASH in 5,400 military personnel and evaluate the effect of treatme...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161118666201015152921

    authors: Sfikas G,Psallas M,Koumaras C,Imprialos K,Perdikakis E,Doumas M,Giouleme O,Karagiannis A,Athyros VG

    更新日期:2020-10-15 00:00:00

  • Metabolic Complications and Kidney Transplantation: Focus on Glycaemia and Dyslipidaemia.

    abstract::Post-transplant diabetes mellitus (PTDM) and dyslipidaemia are the most common metabolic complications in kidney transplant recipients (KTR). They are associated with a higher risk of lower graft function and survival, as well as an increased risk of cardiovascular disease (CVD). The aim of this review is to provide c...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161117666190619143005

    authors: Anagnostis P,Paschou SA,Spartalis E,Sarno G,De Rosa P,Muscogiuri G

    更新日期:2020-01-01 00:00:00

  • Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?

    abstract::Obstructive sleep apnoea (OSA) is characterized by repetitive interruptions of breathing, causing Chronic Intermittent Hypoxia (CIH) that can be involved in the development and progression of cardiovascular diseases. There is evidence showing a close relationship between OSA and atherosclerosis, even in patients who d...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161114666161007164112

    authors: Toraldo DM,Benedetto M,Conte L,De Nuccio F

    更新日期:2017-01-01 00:00:00

  • Occurrence and clinical impact of microembolic signals (MES) in patients with chronic cardiac diseases and atheroaortic plaques--a systematic review.

    abstract:BACKGROUND:In various cardiac diseases, thrombembolism constitutes a major risk, and in these patients clinically silent microembolic signals (MES) are detectable within the transcranial Doppler frequency spectrum (TCD) of the major brain arteries. MES are already an accepted surrogate parameter of the future risk of s...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016108785909797

    authors: Dittrich R,Ringelstein EB

    更新日期:2008-10-01 00:00:00

  • Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases.

    abstract::We evaluated the effects of the glycosaminoglycan sulodexide (SDX; antithrombotic/profibrinolytic drug) on the activity and release of matrix metalloproteinases (MMPs) in human blood. This was a prospective non-randomized study, analyzing by zymography and ELISA the in vitro effects of SDX on pro-enzyme, complexed, an...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161111311030010

    authors: Mannello F,Medda V,Ligi D,Raffetto JD

    更新日期:2013-05-01 00:00:00

  • Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis.

    abstract::Platelet activation induces rapid thrombus formation at a ruptured atherosclerotic plaque leading to acute vessel occlusion and a fatal or non-fatal cardiovascular event. More recent evidence suggests that activated platelets play an additional central role during the initiation of atherosclerosis, essentially facilit...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016108783331295

    authors: Schäfer A,Bauersachs J

    更新日期:2008-01-01 00:00:00

  • New insights into the mechanisms underlying vascular and cardiac effects of urocortin.

    abstract::Urocortin comprises a group of endogenously produced peptide hormones that belong to the corticotropinreleasing factor (CRF) family with promising future as potential drugs for the treatment of heart disease. Members of the urocortin family are known to act as potent regulators of cardiac and vascular functions, throu...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161111311040009

    authors: Díaz I,Smani T

    更新日期:2013-07-01 00:00:00

  • Non-lipid effects of statins: emerging new indications.

    abstract::Statins are beneficial both in the primary and secondary prevention of atherosclerotic vascular disease and acute events in a broad spectrum of patient subgroups. However, the observed clinical benefit with statin therapy is much greater than expected through the reduction of cholesterol levels alone. Clinical and exp...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161043385475

    authors: Yildirir A,Müderrisoglu H

    更新日期:2004-10-01 00:00:00

  • Heart Failure Models: Traditional and Novel Therapy.

    abstract::Cardiovascular disease (CVD) is among the most major causes of morbidity and mortality worldwide. Great progress has been made in the management of CVD which has been influenced by the use of experimental animal models. These models provided information at cellular and molecular levels and allowed the development of t...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161113666150212151506

    authors: Haidara MA,Assiri AS,Yassin HZ,Ammar HI,Obradovic MM,Isenovic ER

    更新日期:2015-01-01 00:00:00

  • New Insight into the Mechanisms of Ginkgo Biloba Extract in Vascular Aging Prevention.

    abstract:BACKGROUND:Aging-associated vascular dysfunction promotes cardiovascular diseases. Recently, Ginkgo biloba extract (GBE) has attracted considerable attention in the prevention of aged vasculature. METHODS:This review discusses the pathophysiological alterations in aged vasculature and the underlying mechanisms of GBE ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161117666190621150725

    authors: Li X,Lu L,Chen J,Zhang C,Chen H,Huang H

    更新日期:2020-01-01 00:00:00

  • Cardiac side effects of chemotherapy: state of art and strategies for a correct management.

    abstract::In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threaten...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111201140327163302

    authors: Perrino C,Schiattarella GG,Magliulo F,Ilardi F,Carotenuto G,Gargiulo G,Serino F,Ferrone M,Scudiero F,Carbone A,Trimarco B,Esposito G

    更新日期:2014-01-01 00:00:00

  • Endothelial Lessons.

    abstract::This essay focuses on nine important lessons learned during more than thirty years of endothelial research. They include: the danger of hiding behind a word, the confusion generated by abbreviations, the need to define the physiological role of the response studied, the local role of endothelium- dependent responses, ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161114666151202204754

    authors: Vanhoutte PM

    更新日期:2016-01-01 00:00:00

  • Cardiovascular diseases and the nitric oxide pathway.

    abstract::Fifteen years after its discovery, NO has fully reached an established position in physiology, medicine and therapeutics. It is difficult to find a biological function or a pathological condition where NO does not play a relevant role. Discoveries in the NO field have historically evolved from cardiovascular research,...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161033476637

    authors: Llorens S,Nava E

    更新日期:2003-10-01 00:00:00

  • Endothelin and oxidative stress in the vascular system.

    abstract::Both endothelin(ET)-1 and oxidative stress have been the subjects of intense investigation within the cardiovascular field over the past decade and a half, yet little is known about the precise relationship between these important modulators of vascular function. There is a firm evidence that ET-1 can stimulate the pr...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016105774329408

    authors: Pollock DM,Pollock JS

    更新日期:2005-10-01 00:00:00

  • The role of nitric oxide on endothelial function.

    abstract::The vascular endothelium is a monolayer of cells between the vessel lumen and the vascular smooth muscle cells. Nitric oxide (NO) is a soluble gas continuously synthesized from the amino acid L-arginine in endothelial cells by the constitutive calcium-calmodulin-dependent enzyme nitric oxide synthase (NOS). This subst...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016112798829760

    authors: Tousoulis D,Kampoli AM,Tentolouris C,Papageorgiou N,Stefanadis C

    更新日期:2012-01-01 00:00:00

  • Functional link between adenosine and insulin: a hypothesis for fetoplacental vascular endothelial dysfunction in gestational diabetes.

    abstract::Gestational diabetes mellitus (GDM) is a syndrome compromising the health of the mother and the fetus. Endothelial damage and reduced metabolism of the vasodilator adenosine occur and fetal hyperinsulinemia associated with deficient insulin response and a metabolic rather than mitogenic phenotype is characteristic of ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111797484062

    authors: Guzmán-Gutiérrez E,Abarzúa F,Belmar C,Nien JK,Ramírez MA,Arroyo P,Salomón C,Westermeier F,Puebla C,Leiva A,Casanello P,Sobrevia L

    更新日期:2011-11-01 00:00:00

  • Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.

    abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the general population. The disease ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma. Several drugs are used in daily clinical practice to manage the disease. However, dat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161115666170621083744

    authors: Imprialos K,Stavropoulos K,Bouloukou S,Kerpiniotis G,Karagiannis A,Doumas M

    更新日期:2018-01-01 00:00:00

  • Endothelial dysfunction in cardiac allograft vasculopathy: potential pharmacological interventions.

    abstract::Nowadays long-term outcome of heart transplantation is limited by a peculiar type of coronary atherosclerosis, known as cardiac allograft vasculopathy (CAV). Although the exact pathogenesis of CAV remains unclear, emerging evidence indicates that the endothelium plays a significant role in the onset and progression of...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110790886992

    authors: Osto E,Tona F,De Bon E,Iliceto S,Cella G

    更新日期:2010-03-01 00:00:00

  • Involvement of coagulation and hemostasis in inflammatory bowel diseases.

    abstract::Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) are idiopathic, intestinal and systemic inflammatory disorders which are immunologically mediated with the activation of plasma proteolytic cascades. The activation of coagulation in IBD is related to the activity and colonic extension of t...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016112801784495

    authors: Stadnicki A

    更新日期:2012-09-01 00:00:00

  • Mechanisms of Cardioprotection of Halogenated Agents During Extracorporeal Circulation in Cardiac Surgery.

    abstract::The implementation of cardioprotective strategies involving pre-, intra-, and postoperative interventions is key during cardiac surgery requiring extracorporeal circulation (ECC). The primary goal of this study was to review the physiopathology and protection strategies against myocardial damage secondary to ECC durin...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161115666171116170806

    authors: Ramirez-Aliaga M,Escalona-Belmonte JJ,Ramirez-Fernandez A,Rubio-Navarro M,Cruz-Manas J

    更新日期:2018-01-01 00:00:00

  • Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.

    abstract::The recently published Assessment of Survival and Cardiovascular Events (AURORA) trial showed that rosuvastatin (10 mg/d) compared with placebo did not result in a significant reduction in vascular events despite a 43% fall in low density lipoprotein cholesterol (LDL-C) levels in patients with end-stage renal disease ...

    journal_title:Current vascular pharmacology

    pub_type: 社论,评审

    doi:10.2174/157016109788340712

    authors: Athyros VG,Tziomalos K,Karagiannis A,Mikhailidis DP

    更新日期:2009-07-01 00:00:00

  • Cardiovascular effects of endogenous estrogen and hormone therapy.

    abstract::The incidence of cardiovascular disease is low in healthy premenopausal women and increases with age especially after the menopause; this difference has been attributed to the loss of endogenous estrogen. Atherosclerosis is a chronic inflammatory condition of the vascular wall that may result in an acute clinical even...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110790886974

    authors: Bechlioulis A,Naka KK,Calis KA,Makrigiannakis A,Michalis L,Kalantaridou SN

    更新日期:2010-03-01 00:00:00